Status:
TERMINATED
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
Lead Sponsor:
Corewell Health East
Conditions:
COVID-19
Acute Respiratory Distress Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also prov...
Detailed Description
There is an urgent need to develop new treatments for Novel Coronavirus-19 (COVID-19) infection using easily available and affordable medications. We need to develop a treatment protocol which prevent...
Eligibility Criteria
Inclusion
- Positive for COVID -19
- Admitted to Beaumont Hospital - Royal Oak, Michigan
- Age ≥18
- Receiving ≤ 6 liters/minute oxygen by nasal cannula for randomization to either placebo or naloxone arm OR receiving ≥ 6 liters/minute oxygen by nasal cannula or requiring advanced oxygenation for placement in ketamine arm
Exclusion
- Known allergy to naltrexone
- Known allergy to ketamine
- Diagnosis of schizophrenia or psychosis
- Pregnancy based on available medical history, existing labs, or verbal report
- On chronic high dose opioids \> 90mg morphine mg equivalence
- Use of naltrexone or Vivitrol within 90 days
Key Trial Info
Start Date :
April 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04365985
Start Date
April 29 2020
End Date
April 1 2021
Last Update
January 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073